Janus Henderson Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$297K Sell
24,915
-1,047,579
-98% -$18M ﹤0.01% 2310
2026
Q2
$26M Buy
1,072,494
+386,568
+56% +$7.3M 0.01% 587
2026
Q1
$11.3M Buy
+685,926
New +$13.1M 0.01% 726
2023
Q4
– Sell
-23,743
Closed -$114K – 2574
2023
Q3
$114K Sell
23,743
-49
-0.2% -$315 ﹤0.01% 2496
2023
Q2
$163K Buy
+23,792
New +$154K ﹤0.01% 2499

Other funds holding GLUE

Janus Henderson Group's GLUE Position: Q3 2026 in Review

Janus Henderson Group reduced its Monte Rosa Therapeutics (GLUE) stake by 98% in Q3 2026, selling an estimated $18M and leaving 24,915 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

Janus Henderson Group first reported a position in GLUE in Q2 2023 and has held it in 5 quarters since. The position peaked at $26M in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Janus Henderson Group held 24,915 shares of Monte Rosa Therapeutics worth $297K as of Q3 2026.
  • Janus Henderson Group sold 1,047,579 Monte Rosa Therapeutics shares in Q3 2026, an estimated $18M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q3 2026, its #2310 holding.
  • Janus Henderson Group first reported a position in Monte Rosa Therapeutics in Q2 2023 and has held it in 5 quarters since.
  • Janus Henderson Group's Monte Rosa Therapeutics position peaked at $26M in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.